دورية أكاديمية
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
| العنوان: | Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study |
|---|---|
| المؤلفون: | Juric, Dejan, Rodon, Jordi, Tabernero Caturla, Josep, Janku, Filip, Burris, Howard A., Schellens, Jan H. M., Middleton, Mark R., Berlin, Jordan, Schuler, Martin, Gil-Martín, Marta, Rugo, Hope S., Seggewiss Bernhardt, Ruth, Huang, Alan, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Coughlin, Christina, Quadt, Cornelia, Baselga Torres, Josep, 1959- |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | Amer Soc Clinical Oncology |
| سنة النشر: | 2018 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Càncer de mama, Tiazoles, Assaigs clínics, Breast cancer, Thiazoles, Clinical trials |
| الوصف: | PurposeWe report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase (PI3K)-selective inhibitor.Patients and MethodsIn the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily.ResultsOne hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses 270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes ( 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 12 p.; application/pdf |
| اللغة: | English |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.7107Test; Journal of Clinical Oncology, 2018, vol. 36, num. 13, p. 1291-1299; https://doi.org/10.1200/JCO.2017.72.7107Test; http://hdl.handle.net/2445/172648Test |
| الإتاحة: | https://doi.org/10.1200/JCO.2017.72.7107Test http://hdl.handle.net/2445/172648Test |
| حقوق: | (c) American Society of Clinical Oncology, 2018 ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8840F1D8 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.8840F1D8 891 3 Academic Journal academicJournal 891.334289550781 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.8840F1D8&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1200/JCO.2017.72.7107# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Juric%2C+Dejan%22">Juric, Dejan</searchLink><br /><searchLink fieldCode="AR" term="%22Rodon%2C+Jordi%22">Rodon, Jordi</searchLink><br /><searchLink fieldCode="AR" term="%22Tabernero+Caturla%2C+Josep%22">Tabernero Caturla, Josep</searchLink><br /><searchLink fieldCode="AR" term="%22Janku%2C+Filip%22">Janku, Filip</searchLink><br /><searchLink fieldCode="AR" term="%22Burris%2C+Howard+A%2E%22">Burris, Howard A.</searchLink><br /><searchLink fieldCode="AR" term="%22Schellens%2C+Jan+H%2E+M%2E%22">Schellens, Jan H. M.</searchLink><br /><searchLink fieldCode="AR" term="%22Middleton%2C+Mark+R%2E%22">Middleton, Mark R.</searchLink><br /><searchLink fieldCode="AR" term="%22Berlin%2C+Jordan%22">Berlin, Jordan</searchLink><br /><searchLink fieldCode="AR" term="%22Schuler%2C+Martin%22">Schuler, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Gil-Martín%2C+Marta%22">Gil-Martín, Marta</searchLink><br /><searchLink fieldCode="AR" term="%22Rugo%2C+Hope+S%2E%22">Rugo, Hope S.</searchLink><br /><searchLink fieldCode="AR" term="%22Seggewiss+Bernhardt%2C+Ruth%22">Seggewiss Bernhardt, Ruth</searchLink><br /><searchLink fieldCode="AR" term="%22Huang%2C+Alan%22">Huang, Alan</searchLink><br /><searchLink fieldCode="AR" term="%22Bootle%2C+Douglas%22">Bootle, Douglas</searchLink><br /><searchLink fieldCode="AR" term="%22Demanse%2C+David%22">Demanse, David</searchLink><br /><searchLink fieldCode="AR" term="%22Blumenstein%2C+Lars%22">Blumenstein, Lars</searchLink><br /><searchLink fieldCode="AR" term="%22Coughlin%2C+Christina%22">Coughlin, Christina</searchLink><br /><searchLink fieldCode="AR" term="%22Quadt%2C+Cornelia%22">Quadt, Cornelia</searchLink><br /><searchLink fieldCode="AR" term="%22Baselga+Torres%2C+Josep%2C+1959-%22">Baselga Torres, Josep, 1959-</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Amer Soc Clinical Oncology ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2018 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Dipòsit Digital de la Universitat de Barcelona ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Càncer+de+mama%22">Càncer de mama</searchLink><br /><searchLink fieldCode="DE" term="%22Tiazoles%22">Tiazoles</searchLink><br /><searchLink fieldCode="DE" term="%22Assaigs+clínics%22">Assaigs clínics</searchLink><br /><searchLink fieldCode="DE" term="%22Breast+cancer%22">Breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Thiazoles%22">Thiazoles</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => PurposeWe report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase (PI3K)-selective inhibitor.Patients and MethodsIn the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily.ResultsOne hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses 270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes ( 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => 12 p.; application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => Reproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.7107; Journal of Clinical Oncology, 2018, vol. 36, num. 13, p. 1291-1299; https://doi.org/10.1200/JCO.2017.72.7107; http://hdl.handle.net/2445/172648 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1200/JCO.2017.72.7107<br />http://hdl.handle.net/2445/172648 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => (c) American Society of Clinical Oncology, 2018 ; info:eu-repo/semantics/openAccess ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.8840F1D8 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Càncer de mama
[Type] => general
)
[1] => Array
(
[SubjectFull] => Tiazoles
[Type] => general
)
[2] => Array
(
[SubjectFull] => Assaigs clínics
[Type] => general
)
[3] => Array
(
[SubjectFull] => Breast cancer
[Type] => general
)
[4] => Array
(
[SubjectFull] => Thiazoles
[Type] => general
)
[5] => Array
(
[SubjectFull] => Clinical trials
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Juric, Dejan
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rodon, Jordi
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tabernero Caturla, Josep
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Janku, Filip
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Burris, Howard A.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schellens, Jan H. M.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Middleton, Mark R.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Berlin, Jordan
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schuler, Martin
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gil-Martín, Marta
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rugo, Hope S.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Seggewiss Bernhardt, Ruth
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Huang, Alan
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bootle, Douglas
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Demanse, David
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Blumenstein, Lars
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Coughlin, Christina
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Quadt, Cornelia
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Baselga Torres, Josep, 1959-
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2018
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |